Diabetes mellitus and diabetes-related complications are common in patients with myelodysplastic syndromes but Hemoglobin A1C is an inadequate marker

Key Points

• To evaluate the prevalence of diabetes and its complications in patients with myelodysplastic syndromes, focusing on the effectiveness of Hemoglobin A1C as a monitoring tool.
• Clinical assessment of patients diagnosed with myelodysplastic syndromes
• Comparison of diabetes prevalence with standard markers
• Analysis of diabetes-related complications within the cohort
• Diabetes mellitus and related complications are prevalent in myelodysplastic syndrome patients.
• Hemoglobin A1C failed to accurately reflect glucose control in this population.
• Alternative markers may be necessary for effective diabetes monitoring.